Galderma Group AGGALDY -0.58%21 EBITDA Margin % is 22.70% as of Dec. 2025, which is 10% above its 10-year median of 20.67. GuruFocus rates GALDY with a GF Score™ of 21/100. The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, Galderma Group AG ranks better than 72.04% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Galderma Group AG's EBITDA for the
six
months ended in Dec. 2025 was $630 Mil. Galderma Group AG's Revenue for the
six
months ended in Dec. 2025 was $2,775 Mil. Therefore, Galderma Group AG's EBITDA margin for the quarter that ended in Dec. 2025 was 22.70%.
Galderma Group AG (OTCPK:GALDY) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Galderma Group AG EBITDA Margin % Related Terms
Galderma Group AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Galderma Group AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GALDY vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galderma Group AG EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Galderma Group AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galderma Group AG (GALDY) has a EBITDA Margin % of 22.70% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Galderma Group AG and its competitors. This is 10% above median its historical median of 20.67. Over the past decade, Galderma Group AG's EBITDA Margin % has ranged from 15.27 to 21.68. According to the industry distribution chart, Galderma Group AG ranks #267 out of 955 companies in the Drug Manufacturers industry, placing it in the top 28%.
Is Galderma Group AG's EBITDA Margin % too high?
Galderma Group AG's current EBITDA Margin % of 22.70% is 10% above median its 10-year median of 20.67. Over the past 10 years, this metric has ranged from a low of 15.27 to a high of 21.68. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Galderma Group AG's value of 22.70% is 82.5% above this industry median. Based on the distribution chart, Galderma Group AG ranks #267 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Galderma Group AG has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #267 out of 955 companies for EBITDA Margin %. This puts Galderma Group AG in the upper half of its industry. The industry median EBITDA Margin % is 12.44. Galderma Group AG's value of 22.70% is 82.5% above this benchmark. Historically, Galderma Group AG's own EBITDA Margin % has ranged from 15.27 to 21.68 over the past decade. While the company's 10-year median is 20.67 vs. the industry median of 12.44, Galderma Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galderma Group AG's current EBITDA Margin % of 22.70% is 82.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Galderma Group AG and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current EBITDA Margin % is 22.70%, which is 10% above median its own 10-year median of 20.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (GALDY) has a current EBITDA Margin % of 22.70%. The current EBITDA Margin % is 22.70%, which is 10% above median its 10-year median of 20.67 and 82.5% above the Drug Manufacturers industry median of 12.44. Galderma Group AG's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Galderma Group AG (GALDY), the current EBITDA Margin % is 22.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
21GF Score
Get the complete analysis for GALDY
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GALDY has been successfully added to your 